{"filings":[{"id":1802796,"accession_number":"0001668397-26-000023","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2026-07-22T20:15:39+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medpace reports Q2 2026 results; no specific figures in filing","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release issued on July 22, 2026 for Q2 2026 results.","No financial data (revenue, EPS, backlog) provided in the 8-K or exhibits.","Results cover three and six months ended June 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":860920,"accession_number":"0001193125-26-257387","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2026-06-04T20:06:40+00:00","items":["5.02"],"status":"ready","headline":"Appoints Brad W. Hansman as EVP, Operations effective June 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brad W. Hansman appointed EVP, Operations effective June 1; will serve as co-principal operating officer with Susan E. Burwig.","Base salary set at $492,250; eligible for short-term incentive (target % per proxy) and discretionary long-term equity grants.","Joined Medpace in 2011 in Finance; led operational functions including study start-up and regulatory affairs since 2015.","No family or material transaction relationships with Medpace; standard indemnification agreement executed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":523356,"accession_number":"0001193125-26-230425","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2026-05-19T18:43:27+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Medpace shareholders approve charter amendments removing supermajority voting and special meeting restrictions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved removal of supermajority voting requirements (24.3M for, 95k against); effective May 18, 2026.","Approved removal of limitation on stockholders calling special meetings; new bylaws require 25% continuous ownership for one year.","Non-binding stockholder proposal on special meetings defeated (8.3M for, 16.1M against); board recommended against.","Advisory say-on-pay passed (22.7M for, 1.7M against); frequency set to annual, consistent with board recommendation.","All five director nominees elected; Deloitte & Touche ratified as auditor for fiscal 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94549,"accession_number":"0001668397-26-000017","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"President Jesse Geiger resigns; CEO Troendle to reassume role; Q1 earnings results not available in filing","summary_kind":"llm","event_type":"leadership","confidence":"low","bullets":["Jesse Geiger to resign as President effective May 31, 2026; not due to disagreement.","CEO August Troendle will reassume President role until a successor is appointed.","Medpace announced Q1 2026 financial results on April 22, 2026, but the press release text was not included in the filing excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107011,"accession_number":"0001668397-26-000004","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medpace reports Q4/FY2025 results; specific figures unavailable from filing","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release issued Feb 9, 2026 for quarter and year ended Dec 31, 2025.","No financial details or guidance changes provided in the 8-K body.","Exhibit 99.1 containing actual results is referenced but not appended in this text."],"consensus_eps_estimate":null,"consensus_eps_actual":15.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":2530234000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123355,"accession_number":"0001668397-25-000108","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medpace reports Q3 2025 earnings; press release unavailable for detail extraction","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Issued press release on October 22, 2025 announcing financial results for three and nine months ended September 30, 2025.","Press release furnished as Exhibit 99.1 but text not provided in this filing excerpt.","Results posted on company website; no specific revenue or EPS figures can be verified from given data."],"consensus_eps_estimate":null,"consensus_eps_actual":10.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":1821784000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140023,"accession_number":"0001668397-25-000085","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Medpace reduces credit line to $10M; Q2 2025 earnings announced, figures not provided","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Amendment No. 9 to credit facility reduces line of credit to $10M, executed July 17, 2025.","Press release for Q2 2025 and H1 2025 results issued July 21, 2025, but exhibit not included in filing.","Specific financial metrics (revenue, EPS, segment data) unavailable from this filing; confidence low.","No guidance or material operational details disclosed in the 8-K filing body."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157639,"accession_number":"0001193125-25-121801","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Medpace stockholders approve amended incentive plan and simple majority voting proposal at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected August J. Troendle (21.2M for) and Dani S. Zander (25.9M for) as Class III directors.","Ratified Deloitte & Touche as independent auditor for FY2025 (27.2M for, 600k against).","Advisory vote to approve named executive officer compensation passed (24.9M for).","Approved 2016 Amended and Restated Incentive Award Plan, extending expiration to Feb 6, 2035 (25.6M for).","Non-binding stockholder proposal for simple majority voting approved (18.2M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157638,"accession_number":"0001668397-25-000056","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["1.01","2.02","8.01","9.01"],"status":"ready","headline":"Medpace increases buyback by $1.0B, expands credit line to $600M; Q1 results released without specifics","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Board approved $1.0B increase to stock repurchase program; timing based on market conditions.","Credit facility amended: line raised to $600M, interest rate adjusted, expiration extended to April 30, 2027.","Q1 2025 earnings press release issued April 21, 2025; specific financial figures not available in this summary.","Credit facility entered with PNC Bank; Amendment No. 8 effective April 18, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176014,"accession_number":"0001668397-25-000037","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Medpace extends revolving credit facility expiration to March 31, 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment No. 7 extends the revolving credit note expiration date to March 31, 2026, representing a one-year extension.","No changes to facility size, interest rate, or other loan terms were disclosed in the amendment.","The amendment was entered into with PNC Bank, National Association, effective March 28, 2025.","Medpace, Inc. is the borrower and Medpace IntermediateCo, Inc. remains the guarantor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176013,"accession_number":"0001668397-25-000012","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Medpace reports Q4/FY24 earnings (no specifics shown) and boosts buyback by $600M","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Issued press release for Q4 and FY2024 results; no financial figures included in filing.","Board approved $600 million increase to existing stock repurchase program.","Repurchases may be made in open market, private deals, or via Rule 10b5-1 plan.","Program can be discontinued or amended at any time without notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192936,"accession_number":"0001668397-24-000165","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2024-10-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medpace reports Q3 2024 results; details not available in extracted exhibit text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release dated October 21, 2024, issued under Item 2.02.","Financial results for three and nine months ended September 30, 2024, announced.","Exhibit 99.1 content not provided; specific figures (revenue, EPS, guidance) unknown.","Results are materially significant but raw data missing from the filing extract."],"consensus_eps_estimate":null,"consensus_eps_actual":8.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":1572465000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209321,"accession_number":"0001668397-24-000140","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2024-07-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medpace Holdings announces Q2 2024 financial results on July 22, 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Medpace Holdings issued a press release on July 22, 2024, reporting financial results for the three and six months ended June 30, 2024.","The press release is attached as Exhibit 99.1 and incorporated by reference under Item 2.02 of the Form 8-K.","Under Item 9.01, the filing includes Exhibit 99.1 and a Cover Page Interactive Data File (Inline XBRL).","The information is furnished and not deemed filed under the Exchange Act or incorporated by reference into other filings."],"consensus_eps_estimate":null,"consensus_eps_actual":5.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":1039148000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209320,"accession_number":"0001193125-24-175077","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Medpace director Ashley Keating resigns; Dr. Dani Zander elected to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ashley M. Keating resigned from the Board effective June 30, 2024, with no disagreement on operations, policies, or practices.","Dr. Dani S. Zander elected as Class III director effective July 1, 2024, and appointed to the Nominating and Governance Committee.","Dr. Zander is Chair of Pathology at University of Cincinnati, formerly at Penn State, and has served as president of multiple pathology societies.","Dr. Zander received an option to purchase 824 shares at the July 1, 2024 closing price, with a 7-year term, under standard non-employee director compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227299,"accession_number":"0001193125-24-143907","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Medpace shareholders approve board declassification; annual director elections start 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to phase out classified board; directors elected annually beginning at 2025 annual meeting.","Fred B. Davenport Jr. and Cornelius P. McCarthy III elected as Class II directors through 2027.","Deloitte & Touche ratified as independent auditor for fiscal year ending December 31, 2024.","Advisory say-on-pay proposal on named executive officer compensation approved.","Charter amendment and bylaw amendments became effective May 17, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227298,"accession_number":"0001668397-24-000089","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2024-04-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medpace reports Q1 2024 results; exhibit not provided, no specific data available","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release filed as Exhibit 99.1 for three months ended March 31, 2024.","No revenue, EPS, or other financial figures are extractable from the available filing text.","Filing indicates earnings announcement but actual results are not included in the provided content."],"consensus_eps_estimate":null,"consensus_eps_actual":3.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":511044000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246177,"accession_number":"0001668397-24-000066","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Medpace reduces revolving credit facility from $150M to $10M, extends to March 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Line of credit reduced to $10M from $150M; expiration extended to March 31, 2025.","Amendment adds new compliance representations on anti-corruption, trade sanctions, and anti-money laundering.","Facility remains unsecured; borrower Medpace Inc. and guarantor Medpace IntermediateCo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246176,"accession_number":"0001668397-24-000008","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2024-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medpace announces Q4 and FY2023 results; no specific figures available in filing text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release posted on company website and furnished as Exhibit 99.1, but exhibit text not included in prompt.","Results cover three and twelve months ended December 31, 2023.","Investors should consult the full press release for revenue, EPS, and other metrics.","Company ticker MEDP trades on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":8.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":1885842000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263625,"accession_number":"0001668397-23-000046","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2023-10-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medpace Q3 2023 earnings: press release issued without specific numbers in excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Medpace issued a press release on October 23, 2023, announcing Q3 2023 financial results.","The filing text does not include the actual earnings figures from the press release.","Specific revenue, EPS, and guidance data are unavailable from the provided exhibit text.","Investors should refer to the full press release on the company's website for details."],"consensus_eps_estimate":null,"consensus_eps_actual":6.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":1387441000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280841,"accession_number":"0001668397-23-000040","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2023-07-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medpace Q2 revenue $469.4M (+27% YoY), EPS $2.35 (+62%); raises FY 2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $469.4M (+27.4% YoY), net income $75.6M (+62.5%), diluted EPS $2.35.","Backlog $2.8B (+18.7%); net new business awards $502.3M (+8.3%).","FY 2023 guidance raised: revenue $1.765B-$1.795B, EPS $8.60-$8.97.","Operating cash flow $120.4M, free cash flow $110.3M in H1; $465M cash, no debt."],"consensus_eps_estimate":null,"consensus_eps_actual":4.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":894942000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299479,"accession_number":"0001668397-23-000036","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2023-05-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Medpace stockholders elect three directors, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Brian T. Carley, Femida H. Gwadry-Sridhar, and Robert O. Kraft as Class I directors until 2026.","Ratified Deloitte & Touche LLP as independent auditor for FY2023 with 28.3M votes for, 0.6M against.","Advisory vote on named executive officer compensation approved: 26.1M for, 1.7M against.","Broker non-votes of 1,172,784 on director elections and say-on-pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299478,"accession_number":"0001668397-23-000029","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2023-04-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medpace announces Q1 2023 results; press release content not included in filing extract","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release dated April 24, 2023, furnished as Exhibit 99.1 but not provided in the supplied text.","Results cover three months ended March 31, 2023; specific financial figures are unavailable.","Q1 2023 earnings release is materially new but cannot be summarized without the exhibit content."],"consensus_eps_estimate":null,"consensus_eps_actual":2.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":434074000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319631,"accession_number":"0001668397-23-000012","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2023-03-31T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Medpace reduces revolving credit line to $150M, extends facility to March 2024","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment No. 5 with PNC Bank cuts the revolving credit facility from $250M to $150M.","Facility expiration extended to March 29, 2024; interest rate and fee terms adjusted.","New Amended and Restated Note executed by Medpace, Inc. (borrower); Medpace IntermediateCo remains guarantor.","Interest rate options: Base Rate plus 0.0% or Term SOFR plus 1.25% per annum for drawn amounts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319630,"accession_number":"0001668397-23-000003","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2023-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medpace Q4/FY2022 earnings release; detailed results not available in filing text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Medpace issued a press release on February 13, 2023 for Q4 and full year 2022 results.","The full text of the press release is referenced as Exhibit 99.1 but not included in provided text.","Without exhibit content, specific revenue, EPS, or guidance changes cannot be summarized.","Investors should refer to the company's website or subsequent filings for financial details."],"consensus_eps_estimate":null,"consensus_eps_actual":7.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":1459996000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319629,"accession_number":"0001193125-23-010261","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2023-01-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Medpace appoints Dr. Femida H. Gwadry-Sridhar as new Class I director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Gwadry-Sridhar appointed to Board effective Jan 16, 2023, filling a Class I vacancy.","She is CEO of Pulse Infoframe, a real-world evidence company, with academic roles at Western University and USC.","Received an option to purchase 573 shares at Jan 13 closing price, with 7-year term.","Expected to serve on the Nominating and Governance Committee.","Participates in standard non-employee director compensation program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319628,"accession_number":"0001193125-23-000776","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2023-01-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Thomas C. King resigns from Medpace Board effective Dec 31, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas C. King notified Medpace of his resignation from the Board on December 31, 2022.","Resignation effective immediately; no disagreement with company operations, policies, or practices.","No replacement named; remaining board composition unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337834,"accession_number":"0001668397-22-000006","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2022-10-24T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Medpace Q3 earnings released; Board authorizes $500M share buyback","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Board authorized share repurchases of up to $500M of common stock on Oct 21, 2022.","Repurchases at management's discretion with no minimum obligation.","Q3 2022 financial results press released on Oct 24; specific numbers not included in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355192,"accession_number":"0000950170-22-012986","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2022-07-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medpace reports Q2 2022 revenue $351.2M (+26.2% YoY), diluted EPS $1.46 vs $1.06","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $351.2M, up 26.2% YoY; constant currency organic growth 27.7%.","GAAP net income $49.4M ($1.46 diluted EPS) vs $39.9M ($1.06) YoY.","Net new business awards $450.6M (book-to-bill 1.28x), up 16.3% YoY.","Backlog $2.2B, up 24.4% from $1.7B YoY.","EBITDA $68.1M (19.4% margin), up 42% YoY from $47.9M (17.2%)."],"consensus_eps_estimate":null,"consensus_eps_actual":3.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":682154000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373307,"accession_number":"0001193125-22-171965","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Medpace Board approves $50M increase to share repurchase program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board of Directors approved $50M increase to existing stock repurchase program on June 10, 2022.","Repurchases may occur in open market, privately negotiated transactions, or via Rule 10b5-1 plans.","Timing, price, and volume depend on market conditions and securities laws; program can be discontinued anytime."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373306,"accession_number":"0001193125-22-161052","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2022-05-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Medpace boosts buyback by $60M; retired 1.6M shares (~5% of float) in past month","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved $60M increase to existing stock repurchase program on May 25, 2022.","From Apr 22 to May 25, 2022, repurchased 1,597,007 shares for treasury.","Repurchases reduced outstanding shares by approximately 5% to 32,065,701 as of May 25.","Timing and volume of future repurchases depend on market conditions and securities laws.","Program may be discontinued or amended at any time without notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373305,"accession_number":"0001193125-22-156274","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2022-05-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Medpace 2022 annual meeting: director Keating gets more withheld than 'for' votes; say-on-pay passes 72%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors August Troendle and Ashley Keating elected to Class III board; Keating received 12,863,441 for vs. 17,722,711 withheld.","Ratification of Deloitte & Touche as FY2022 auditor passed with 30,576,845 votes for (96.5% of votes cast).","Advisory say-on-pay proposal approved with 22,093,994 votes for (72.3% excluding broker non-votes) and 8,458,621 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373304,"accession_number":"0000950170-22-006093","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2022-04-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medpace Q1 revenue up 27.3% to $330.9M; EPS $1.69 vs $1.14 YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $330.9M, +27.3% YoY; constant-currency organic growth +28.1%.","GAAP EPS $1.69 diluted vs $1.14 prior year; net income margin 18.5% (prev 16.7%).","Net new business awards $423.0M (+18.8% YoY); book-to-bill ratio 1.28x.","Backlog grew 28.0% to $2.1B from $1.6B as of Mar 31, 2021.","EBITDA $70.4M (+31.3%); margin 21.3% vs 20.6% prior year."],"consensus_eps_estimate":null,"consensus_eps_actual":1.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":330947000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392049,"accession_number":"0000950170-22-003943","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2022-03-16T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Medpace increases credit facility to $250M and expands share buyback by $200M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 4 raises line of credit from $50M to $250M with PNC Bank, maturing March 31, 2023.","Board approved $200M increase to stock repurchase program; 1,782,136 shares repurchased since Feb 11, 2022.","Repurchases reduced outstanding shares by ~5%; 33,723,904 shares outstanding as of March 14, 2022.","Interest options include Base Rate or Term SOFR +1.00%; anti-money laundering compliance updated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392048,"accession_number":"0000950170-22-001213","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2022-02-14T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Medpace Q4 revenue up 18.8% to $308.6M; full year revenue +23.4%; Board approves $300M buyback increase","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 GAAP net income $50.0M ($1.32 EPS) vs $50.9M ($1.35 EPS) prior year; net income margin 16.2%.","Full year 2021 GAAP net income $181.8M ($4.81 EPS) vs $145.4M ($3.84 EPS); net income margin 15.9%.","Net new business awards Q4 $458.7M (book-to-bill 1.49x), up 27.9% YoY; backlog $1,997.1M (+29.5%).","EBITDA Q4 $61.4M (19.9% margin) vs $60.2M (23.2%) prior year; full year EBITDA $223.1M (19.5% margin).","Board increased stock repurchase program by $300 million; program has no set expiration."],"consensus_eps_estimate":null,"consensus_eps_actual":4.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":1142377000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410369,"accession_number":"0000950170-21-005380","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2021-12-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Medpace extends $50M credit facility to March 2023; adopts LIBOR replacement terms","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment extends revolving credit note expiration to March 31, 2023.","Removes ability to obtain advances in currencies other than U.S. dollars.","Adds LIBOR Replacement Rider with Term SOFR or Daily Simple SOFR fallback provisions.","Facility is an unsecured credit line up to $50 million with PNC Bank.","Guarantor Medpace IntermediateCo, Inc. consents and confirms obligations unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410368,"accession_number":"0000950170-21-002274","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2021-10-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medpace Q3 revenue $295.6M (+28.3%), EPS $1.29; net new awards $408M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $295.6M, up 28.3% YoY; net income $48.6M ($1.29 diluted EPS) vs $41.5M ($1.09) prior year.","Net new business awards $408M, up 29.4%, book-to-bill 1.38x; backlog $1.8B (+29%).","EBITDA $60.1M (20.3% margin) vs $51.9M (22.5%) prior year; net income margin 16.4% vs 18%.","Constant currency organic revenue growth 28.1%."],"consensus_eps_estimate":null,"consensus_eps_actual":3.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":833825000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":429171,"accession_number":"0001564590-21-037944","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2021-07-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medpace Q2 2021 revenue up 35.8% to $278.3M; net income $39.9M ($1.06 EPS)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net new business awards of $387.6M (+52.5% YoY) produced a 1.39x book-to-bill ratio.","Backlog grew 29.8% to $1.7B; revenue backlog conversion rate 17.1%.","EBITDA $47.9M (17.2% margin), up 36.9% YoY; GAAP net income margin 14.3%.","Direct costs $203.6M vs $148.4M; SG&A $27.0M vs $21.9M in prior-year quarter.","On a constant currency basis, organic revenue grew 34.4% and EBITDA grew 41.5%."],"consensus_eps_estimate":null,"consensus_eps_actual":2.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":538258000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":429170,"accession_number":"0001193125-21-224356","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2021-07-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Medpace appoints Jesse Geiger as President, Kevin Brady as CFO effective Aug 1","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jesse Geiger, formerly CFO and COO of laboratory ops, becomes President; August Troendle remains Chairman & CEO.","Kevin Brady, formerly Executive Director of Finance and Treasurer, promoted to CFO effective August 1, 2021.","Brady's CFO compensation: $340,000 annual base salary plus short-term and long-term incentive eligibility.","Brady will continue as Treasurer and report to Geiger; Geiger reports to Troendle."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":429169,"accession_number":"0001193125-21-223035","cik":1668397,"company_name":"Medpace Holdings, Inc.","ticker":"MEDP","form_type":"8-K","filed_at":"2021-07-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Medpace Holdings establishes Nominating and Governance Committee","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board created a Nominating and Governance Committee effective July 22, 2021.","Committee members: Brian T. Carley, Fred B. Davenport Jr., Ashley M. Keating, Thomas C. King, Robert O. Kraft, Cornelius P. McCarthy III.","All six members are independent under NASDAQ listing standards.","Committee will identify director nominees, recommend governance guidelines, and fill board vacancies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":12744761023.361565,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}